GO:0090107 regulation of high-density lipoprotein particle assembly: HDL Biogenesis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090107 describes any process that modulates the frequency, rate, or extent of high-density lipoprotein (HDL) particle assembly, the aggregation and arrangement of proteins and lipids into an HDL particle.
• The ABCA1/apolipoprotein pathway is the central route for HDL assembly, with apolipoprotein A-I (APOA1) as the principal protein scaffold and ABCA1 as the rate-limiting lipid transporter.
• ABCA7 provides an alternative HDL-generating activity, producing particles with distinct size and lipid heterogeneity compared with ABCA1.
• Phosphatidylcholine biosynthesis supplies the phospholipid substrate required for HDL particle formation and is therefore a regulatory node for this GO term.
• Pharmacological modulation of lipoprotein metabolism, such as niacin treatment, can alter HDL assembly and catabolism, linking this process to therapeutic intervention.
• Dysregulation of HDL assembly is mechanistically linked to atherosclerosis and inflammatory microdomain remodeling in the arterial wall.
Description
GO:0090107, regulation of high-density lipoprotein particle assembly, is a biological_process term in the Gene Ontology that captures any process modulating the frequency, rate, or extent of HDL particle assembly. HDL particle assembly itself is defined as the aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle. Because HDL particles are the principal mediators of reverse cholesterol transport and are strongly associated with cardiovascular health, understanding how their assembly is regulated is a central question in lipoprotein biology. The assembly reaction is not a single event but a coordinated membrane-associated process in which lipid transporters, apolipoproteins, and phospholipid biosynthetic enzymes converge. The best-characterized assembly route is the ABCA1/apolipoprotein pathway, in which ABCA1 translocates phospholipid and cholesterol to lipid-poor apolipoprotein A-I, generating nascent discoidal HDL. A parallel pathway involving ABCA7 generates HDL particles with distinct heterogeneity, indicating that multiple regulatory inputs shape the final HDL pool. Because HDL assembly sits at the intersection of lipid metabolism, membrane biology, and inflammation, researchers studying atherosclerosis, metabolic disease, and lipid disorders routinely interrogate this GO term. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, genes, disease links, and experimental methods relevant to GO:0090107.
regulation of high-density lipoprotein particle assembly At A Glance
| GO ID | GO:0090107 |
|---|---|
| GO term | regulation of high-density lipoprotein particle assembly |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that modulates the frequency, rate, or extent of high-density lipoprotein particle assembly; HDL particle assembly is the aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle. |
| Major function | Controls the rate and extent of HDL particle formation, thereby influencing circulating HDL levels and reverse cholesterol transport capacity. |
| Key molecular players | ABCA1, ABCA7, APOA1, and phosphatidylcholine biosynthetic enzymes. |
| Substrate context | Phospholipids and cholesterol transferred to lipid-poor apolipoproteins. |
| Disease relevance | Atherosclerosis, inflammation, and lipoprotein metabolism disorders. |
What Is GO:0090107?
In plain terms, GO:0090107 is the regulatory layer that controls how often, how fast, and how extensively HDL particles are built. The term does not describe the assembly reaction itself but any process that modulates it, including changes in the activity, abundance, or localization of the proteins and lipids that carry out assembly. The underlying assembly process is the aggregation and arrangement of proteins and lipids into a high-density lipoprotein particle, a step that requires apolipoproteins, lipid transporters, and phospholipid substrates.
Why Is regulation of high-density lipoprotein particle assembly Important in Cell Biology?
Regulation of HDL particle assembly is important because HDL particles are the primary vehicles for reverse cholesterol transport, the process by which excess cholesterol is removed from peripheral tissues and returned to the liver for excretion. The rate at which HDL particles are assembled directly influences plasma HDL concentration and function, which are classic biomarkers of cardiovascular risk. Because assembly is regulated rather than constitutive, it represents a tunable node for therapeutic intervention in dyslipidemia and atherosclerosis. Moreover, the membrane microdomains and lipid transporters involved in HDL assembly overlap with inflammatory signaling platforms, connecting this GO term to vascular inflammation and plaque biology. For researchers, GO:0090107 provides a precise ontological handle for annotating genes and experiments that modulate HDL biogenesis, enabling consistent interpretation across transcriptomic, proteomic, and functional studies.
• HDL assembly determines circulating HDL levels, a major inverse predictor of atherosclerotic cardiovascular disease.
• The ABCA1/apolipoprotein pathway is the rate-limiting route for nascent HDL formation and a direct drug target.
• ABCA7-mediated assembly generates HDL particles with distinct heterogeneity, expanding the regulatory landscape.
• Phosphatidylcholine biosynthesis controls the phospholipid supply needed for HDL particle formation.
• Niacin and other lipid-modulating agents alter lipoprotein metabolism, including HDL assembly and catabolism.
• Membrane microdomains involved in HDL assembly intersect with inflammatory signaling in atherosclerosis.
• Genes annotated to GO:0090107 are candidates for functional genomics studies of lipid disorders.
• Understanding assembly regulation supports development of HDL-targeted therapeutics.
• The term enables consistent Gene Ontology annotation across lipidomics and transcriptomics datasets.
• Dysregulated HDL assembly is mechanistically linked to impaired reverse cholesterol transport.
What Happens During regulation of high-density lipoprotein particle assembly?
Initiation at the cell membrane: ABCA1 and lipid-poor apolipoproteins
In simple terms: The assembly line starts when a transporter on the cell surface hands lipids to a bare apolipoprotein protein.
HDL assembly begins at the plasma membrane, where the ATP-binding cassette transporter ABCA1 mediates the transfer of phospholipid and cholesterol to lipid-poor apolipoprotein A-I (APOA1). This interaction converts lipid-free APOA1 into a nascent discoidal HDL particle. The ABCA1/apolipoprotein pathway is considered the principal and rate-limiting route for HDL biogenesis, and its activity is a major determinant of plasma HDL concentration. Regulation of this step therefore directly modulates the frequency and extent of HDL particle assembly, consistent with the GO:0090107 definition.
Alternative assembly via ABCA7 and particle heterogeneity
In simple terms: A second transporter can also build HDL particles, but the particles it makes look different from those made by the main transporter.
ABCA7 provides an alternative HDL-generating activity that produces particles with distinct size and lipid composition compared with ABCA1-generated HDL. This heterogeneity indicates that regulation of HDL particle assembly is not governed by a single transporter but by the relative contribution of multiple lipid efflux proteins. The existence of parallel assembly routes means that regulatory inputs acting on ABCA1 versus ABCA7 can reshape the HDL pool, which is directly relevant to the biological_process defined by GO:0090107.
Phospholipid substrate supply and phosphatidylcholine biosynthesis
In simple terms: Building an HDL particle requires raw phospholipid material, and the cell must make enough of it.
Phosphatidylcholine biosynthesis is required to supply the phospholipid substrate for lipoprotein assembly, including HDL. Because phospholipids are the major surface component of HDL particles, the rate of phosphatidylcholine production can set a ceiling on how much HDL can be assembled. Regulatory processes that alter phosphatidylcholine biosynthetic enzyme expression or activity therefore modulate HDL particle assembly, placing this metabolic pathway within the scope of GO:0090107.
Membrane microdomains and the inflammatory interface
In simple terms: The cell membrane is not uniform; specialized patches where assembly happens also participate in inflammation.
HDL assembly occurs in specialized membrane microdomains that are also platforms for inflammatory signaling. The overlap between lipid efflux machinery and inflammatory microdomains means that inflammatory stimuli can influence the efficiency of HDL particle assembly. This crosstalk provides a mechanistic explanation for why chronic inflammation is associated with altered HDL levels and function, and it identifies microdomain organization as a regulatory layer for GO:0090107.
Pharmacological modulation of lipoprotein metabolism
In simple terms: Drugs that change how the body handles fats can also change how HDL particles are built.
Niacin is a well-characterized agent that modifies lipoprotein metabolism, including effects on HDL. Pharmacological manipulation of lipoprotein metabolism demonstrates that HDL assembly and catabolism are regulatable processes amenable to therapeutic intervention. Such interventions provide experimental evidence that the frequency and extent of HDL particle assembly can be modulated, which is the essence of GO:0090107.
Key Genes Involved in GO:0090107 regulation of high-density lipoprotein particle assembly
The following genes and proteins are experimentally implicated in the regulation of HDL particle assembly and related lipoprotein metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | Mediates transfer of phospholipid and cholesterol to lipid-poor APOA1, initiating nascent HDL assembly | Rate-limiting transporter for HDL biogenesis; primary target for functional studies of GO:0090107 |
| APOA1 | Principal apolipoprotein scaffold of HDL; accepts lipids from ABCA1 | Central structural protein for HDL particle formation assays |
| ABCA7 | Alternative lipid transporter generating HDL particles with distinct heterogeneity | Model for studying parallel assembly routes and HDL subpopulation diversity |
| APOA2 | Apolipoprotein component of HDL particles | Marker of HDL composition and metabolism |
| APOE | Apolipoprotein involved in lipoprotein metabolism and cholesterol transport | Relevant to HDL-related lipid transport and disease models |
| LCAT | Enzyme that esterifies cholesterol on HDL particles, maturing nascent HDL | Key maturation factor downstream of assembly |
| CETP | Mediates transfer of cholesteryl esters between lipoproteins, remodeling HDL | Modulates HDL pool size and composition |
| PLTP | Phospholipid transfer protein involved in HDL remodeling | Affects HDL particle size and phospholipid content |
| SCARB1 | HDL receptor mediating selective cholesterol uptake | Links HDL assembly to reverse cholesterol transport |
| APOC3 | Apolipoprotein that modulates lipoprotein metabolism | Relevant to HDL and triglyceride metabolism crosstalk |
| LIPC | Hepatic lipase involved in HDL remodeling | Affects HDL particle size and catabolism |
| LPL | Lipoprotein lipase involved in lipoprotein metabolism | Indirect regulator of HDL pool via triglyceride-rich lipoprotein processing |
| PEMT | Phosphatidylethanolamine N-methyltransferase contributing to phosphatidylcholine synthesis | Supports phospholipid substrate supply for HDL assembly |
| CHKA | Choline kinase alpha, first enzyme in phosphatidylcholine biosynthesis | Regulates phospholipid supply for lipoprotein assembly |
| CEPT1 | Choline/ethanolamine phosphotransferase in phosphatidylcholine synthesis | Contributes to phospholipid substrate availability |
| NR1H3 | Liver X receptor alpha, transcription factor regulating lipid metabolism genes | Upstream transcriptional regulator of HDL assembly genes |
| PPARA | Peroxisome proliferator-activated receptor alpha, regulator of lipid metabolism | Modulates lipoprotein metabolism including HDL |
| APOM | Apolipoprotein M associated with HDL particles | Marker of HDL subpopulation composition |
How Is regulation of high-density lipoprotein particle assembly Regulated?
Regulation of HDL particle assembly is exerted at multiple levels. Transcriptionally, nuclear receptors such as liver X receptor alpha (NR1H3) control expression of lipid metabolism genes including ABCA1, thereby setting the capacity for HDL assembly. At the substrate level, phosphatidylcholine biosynthesis determines phospholipid availability for particle formation. Pharmacological regulation by niacin demonstrates that lipoprotein metabolism, including HDL assembly and catabolism, can be systematically modulated. In addition, the membrane microdomain environment in which assembly occurs is subject to inflammatory regulation, providing a further layer of control. Together, these transcriptional, metabolic, and pharmacological inputs define the regulatory scope of GO:0090107.
regulation of high-density lipoprotein particle assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCA1 | Atherosclerosis and impaired HDL biogenesis | ABCA1 knockout cell model with APOA1 efflux assay |
| APOA1 | HDL deficiency and cardiovascular risk | APOA1 knock-in or overexpression hepatocyte model |
| ABCA7 | HDL heterogeneity and lipid metabolism | ABCA7 knockout versus ABCA1 knockout comparative model |
| PEMT | Phospholipid supply and lipoprotein assembly | PEMT knockout hepatocyte model with lipidomics |
| NR1H3 | Transcriptional control of lipid metabolism | NR1H3 knockout or overexpression macrophage model |
Atherosclerosis and cardiovascular disease
HDL particles mediate reverse cholesterol transport, and their assembly rate influences circulating HDL levels, which are inversely associated with atherosclerotic cardiovascular disease. Dysregulation of HDL assembly can reduce the capacity to remove cholesterol from peripheral tissues, contributing to plaque formation. Membrane microdomains involved in HDL assembly also participate in inflammatory signaling within the arterial wall, linking assembly regulation to atherogenesis.
Inflammation and vascular biology
The overlap between HDL assembly machinery and inflammatory microdomains means that inflammatory states can alter HDL particle formation and function. This crosstalk helps explain the observation that chronic inflammatory conditions are often accompanied by altered HDL levels and composition. Researchers studying vascular inflammation therefore treat GO:0090107 as a mechanistically relevant process.
Lipoprotein metabolism disorders and therapeutic modulation
Disorders of lipoprotein metabolism can involve altered HDL assembly and catabolism. Pharmacological agents such as niacin modify lipoprotein metabolism, including effects on HDL, demonstrating that these pathways are clinically actionable. Understanding the regulation of HDL particle assembly supports the development of therapies aimed at improving HDL function.
From regulation of high-density lipoprotein particle assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ABCA1 abolish HDL particle assembly? | ABCA1 knockout cell line with APOA1 efflux and HDL particle sizing |
| Does a point mutation in APOA1 alter lipid binding? | APOA1 point-mutation knock-in cell model |
| Can ABCA7 compensate for ABCA1 loss in HDL assembly? | ABCA7 overexpression in ABCA1 knockout background |
| Does tagging endogenous ABCA1 affect its trafficking? | Tagged knock-in ABCA1 cell line for imaging |
| Does increased phosphatidylcholine synthesis boost HDL assembly? | CHKA or PEMT overexpression hepatocyte model |
| Does niacin treatment change HDL assembly rate? | Pharmacological treatment of hepatocyte or macrophage models |
How to Study the regulation of high-density lipoprotein particle assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cholesterol efflux assay | Transfer of cholesterol from cells to APOA1 | Quantifying HDL assembly capacity in knockout or overexpression cells |
| Phospholipid efflux assay | Transfer of phospholipids to lipid-poor apolipoproteins | Assessing ABCA1-dependent assembly |
| Lipoprotein profiling | HDL particle size and subpopulation distribution | Comparing assembly outcomes across genotypes |
| Lipidomics | Phospholipid and cholesterol species | Measuring substrate availability for assembly |
| RNA sequencing | Expression of HDL assembly genes | Identifying transcriptional regulators of GO:0090107 |
| Quantitative proteomics | Protein abundance of ABCA1, ABCA7, APOA1 | Validating changes in assembly machinery |
| Fluorescence imaging | Localization of transporters and apolipoproteins | Studying membrane microdomain involvement |
| Pharmacological treatment assays | Effect of drugs on lipoprotein metabolism | Testing modulators of HDL assembly |
Lipid efflux and HDL assembly assays
Cellular cholesterol and phospholipid efflux assays using labeled APOA1 are standard methods to measure HDL assembly capacity. These assays quantify the transfer of lipids from cells to lipid-poor apolipoproteins, directly reporting on the assembly step regulated by GO:0090107. Combining efflux assays with particle sizing provides a readout of nascent HDL formation.
Lipoprotein profiling and lipidomics
Lipoprotein profiling separates HDL subpopulations and quantifies particle size and composition, which reflects the outcome of regulated assembly. Lipidomic analysis measures phospholipid and cholesterol species that serve as substrates for assembly. These methods are essential for linking molecular perturbations to changes in the HDL pool.
Transcriptomic and proteomic analysis of assembly genes
RNA sequencing and quantitative proteomics can quantify expression of genes annotated to GO:0090107, such as ABCA1, ABCA7, and APOA1. Such datasets reveal transcriptional and post-transcriptional regulatory layers controlling HDL assembly capacity. Integrating these data with lipid phenotypes helps identify causal regulators.
Imaging of membrane microdomains and transporter localization
Fluorescence imaging of ABCA1 and apolipoproteins at the plasma membrane reveals where HDL assembly occurs and how microdomain organization influences it. Because assembly takes place in specialized membrane regions that also host inflammatory signaling, imaging connects spatial regulation to function. Tagged knock-in models enable tracking of endogenous proteins.
How CRISPR Can Be Used to Study GO:0090107 regulation of high-density lipoprotein particle assembly
Knockout
CRISPR knockout of ABCA1, ABCA7, or APOA1 provides a clean genetic test of their requirement for HDL particle assembly. Knockout cell models can be subjected to cholesterol and phospholipid efflux assays to quantify loss of assembly capacity. Comparative knockouts of ABCA1 versus ABCA7 reveal the relative contribution of each transporter to HDL heterogeneity.
Point Mutation
Point-mutation knock-in of residues in APOA1 or ABCA1 allows structure-function analysis of lipid binding and transport. Such models test whether specific amino acids are required for the assembly reaction without eliminating the entire protein. Point mutants can be compared with wild-type cells in efflux and particle sizing assays.
Knock-in
Knock-in of tagged or reporter versions of ABCA1 and APOA1 enables tracking of endogenous assembly machinery. Tagged knock-in models support imaging of transporter trafficking and membrane microdomain localization. Knock-in of disease-associated variants can model altered HDL assembly in a physiological context.
Overexpression
Overexpression of ABCA7, CHKA, or PEMT tests whether increasing transporter or phospholipid synthesis capacity enhances HDL assembly. Overexpression models are useful for gain-of-function studies of GO:0090107 regulation. Combining overexpression with knockout backgrounds can reveal compensatory pathways.
How EDITGENE Supports regulation of high-density lipoprotein particle assembly Research
Researchers studying regulation of high-density lipoprotein particle assembly-related genes often need to determine whether a candidate gene is causally involved in HDL biogenesis or merely correlated with it. Establishing causality requires controlled genetic perturbation, ideally in isogenic cell models where a single gene is knocked out, mutated, or overexpressed. EDITGENE provides end-to-end CRISPR services to generate such models and to interpret the resulting lipid and transcriptomic phenotypes.
Contact EDITGENE today to design your custom CRISPR model for regulation of high-density lipoprotein particle assembly research.
Frequently Asked Questions About regulation of high-density lipoprotein particle assembly
What is GO:0090107?
GO:0090107 is the Gene Ontology biological_process term for regulation of high-density lipoprotein particle assembly, defined as any process that modulates the frequency, rate, or extent of HDL particle assembly.
What is high-density lipoprotein particle assembly?
It is the aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle, primarily mediated by the ABCA1/apolipoprotein pathway.
What genes are involved in regulation of high-density lipoprotein particle assembly?
Key genes include ABCA1, APOA1, ABCA7, and phosphatidylcholine biosynthetic enzymes such as CHKA and PEMT.
How is HDL particle assembly regulated?
It is regulated transcriptionally by nuclear receptors such as NR1H3, by phospholipid substrate supply, by membrane microdomain organization, and pharmacologically by agents such as niacin.
Why is regulation of HDL particle assembly important for disease?
Because HDL mediates reverse cholesterol transport, and its assembly rate influences circulating HDL levels and atherosclerotic cardiovascular disease risk.
What is the role of ABCA1 in HDL assembly?
ABCA1 transfers phospholipid and cholesterol to lipid-poor APOA1, generating nascent discoidal HDL and serving as the rate-limiting step in HDL biogenesis.
How does ABCA7 differ from ABCA1 in HDL assembly?
ABCA7 generates HDL particles with distinct size and lipid heterogeneity compared with ABCA1, providing an alternative assembly route.
Can CRISPR be used to study HDL particle assembly?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes such as ABCA1 and APOA1 in HDL assembly assays.
What methods measure HDL particle assembly?
Cholesterol and phospholipid efflux assays, lipoprotein profiling, lipidomics, RNA sequencing, proteomics, and fluorescence imaging are commonly used.
What diseases are linked to dysregulated HDL assembly?
Atherosclerosis, inflammation-associated vascular disease, and lipoprotein metabolism disorders are linked to altered HDL assembly.
Conclusion
GO:0090107, regulation of high-density lipoprotein particle assembly, defines the regulatory processes that control how HDL particles are built. The ABCA1/apolipoprotein pathway is the central assembly route, with ABCA7 providing an alternative and phosphatidylcholine biosynthesis supplying essential phospholipid substrate. Because HDL assembly determines circulating HDL levels and reverse cholesterol transport capacity, its regulation is directly relevant to atherosclerosis, inflammation, and lipoprotein disorders. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with efflux assays, lipidomics, and transcriptomics, provide the experimental toolkit needed to dissect this process and identify causal regulators.
References
- 1. Yokoyama S. 2006. Assembly of high-density lipoprotein.. Arterioscler Thromb Vasc Biol 26(1):20-7 PMID: 16284193
- 2. Illingworth DR. 1993. Lipoprotein metabolism.. Am J Kidney Dis 22(1):90-7 PMID: 8322800
- 3. Ginsberg HN. 1998. Lipoprotein physiology.. Endocrinol Metab Clin North Am 27(3):503-19 PMID: 9785050
- 4. Yokoyama S. 2005. Assembly of high density lipoprotein by the ABCA1/apolipoprotein pathway.. Curr Opin Lipidol 16(3):269-79 PMID: 15891387
- 5. Sorci-Thomas MG et al.. 2016. Microdomains, Inflammation, and Atherosclerosis.. Circ Res 118(4):679-91 PMID: 26892966
- 6. Hayashi M et al.. 2005. Heterogeneity of high density lipoprotein generated by ABCA1 and ABCA7.. J Lipid Res 46(8):1703-11 PMID: 15930518
- 7. Cole LK et al.. 2012. Phosphatidylcholine biosynthesis and lipoprotein metabolism.. Biochim Biophys Acta 1821(5):754-61 PMID: 21979151
- 8. Kamanna VS et al.. 2000. Mechanism of action of niacin on lipoprotein metabolism.. Curr Atheroscler Rep 2(1):36-46 PMID: 11122723
